PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Altering cellular interactions around amyloid plaques may offer novel Alzheimer’s treatment strategies

Innovative research from Mount Sinai also identifies new pathways for research

Altering cellular interactions around amyloid plaques may offer novel Alzheimer’s treatment strategies
2024-05-27
(Press-News.org)

New York City, [May 27, 2024] – Researchers at the Icahn School of Medicine at Mount Sinai have made a significant breakthrough in Alzheimer’s disease research by identifying a novel way to potentially slow down or even halt disease progression. The study, which focuses on the role of reactive astrocytes and the plexin-B1 protein in Alzheimer's pathophysiology, provides crucial insights into brain cell communication and opens the door to innovative treatment strategies. It was published in Nature Neuroscience (DOI 10.1038/s41593-024-01664-w) on May 27. 

 

This groundbreaking work is centered on the manipulation of the plexin-B1 protein to enhance the brain's ability to clear amyloid plaques, a hallmark of Alzheimer’s disease. Reactive astrocytes, a type of brain cell that becomes activated in response to injury or disease, were found to play a crucial role in this process. They help control the spacing around amyloid plaques, affecting how other brain cells can access and clear these harmful deposits. “Our findings offer a promising path for developing new treatments by improving how cells interact with these harmful plaques,” said Roland Friedel, PhD, Associate Professor of Neuroscience, and Neurosurgery, at Icahn Mount Sinai and a senior author of the study. The research was driven by the analysis of complex data comparing healthy individuals to those with Alzheimer’s, aiming to understand the disease's molecular and cellular foundations.

 

Hongyan Zou, PhD, Professor of Neurosurgery, and Neuroscience, at Icahn Mount Sinai and one of the study’s lead authors, highlighted the broader implications of their findings: “Our study opens new pathways for Alzheimer’s research, emphasizing the importance of cellular interactions in developing neurodegenerative disease treatments.”

 

One of the study’s most significant achievements is its validation of multiscale gene network models of Alzheimer’s disease. “This study not only confirms one of the most important predictions from our gene network models but also significantly advances our understanding of Alzheimer’s. It lays a solid foundation for developing novel therapeutics targeting such highly predictive network models,” said Bin Zhang, PhD, Willard T.C. Johnson Research Professor of Neurogenetics at Icahn Mount Sinai and one of the study’s lead authors. By demonstrating the critical role of plexin-B1 in Alzheimer's disease, the research underscores the potential of targeted therapies to disrupt the disease's progression.

 

The research team emphasizes that while their findings mark a significant advance in the fight against Alzheimer’s, more research is needed to translate these discoveries into treatments for human patients.

 

“Our ultimate goal is to develop treatments that can prevent or slow down Alzheimer’s progression,” Dr. Zhang added, outlining the team’s commitment to further exploring the therapeutic potential of plexin-B1.

 

This study is supported by the NIH National Institute on Aging (NIA) grants U01AG046170 and RF1AG057440 and is part of the NIA-led Accelerating Medicines Partnership - Alzheimer's Disease (AMP-AD) Target Discovery and Preclinical Validation program. This public private partnership aims to shorten the time between the discovery of potential drug targets and the development of new drugs for Alzheimer’s disease treatment and prevention.

 

The paper is titled “Regulation of cell distancing in peri-plaque glial nets by Plexin-B1 affects glial activation and amyloid compaction in Alzheimer’s disease.” 

 

 

 

-####-

 

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight- member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.  

 

Ranked 13th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 44 academic departments and 36 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases. 

 

Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System. 

 

A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into healthcare products and services that benefit the public. 

 

Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs. 

 

Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others. 

 

The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally. 

------------------------------------------------------- 

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai. 

 

END


[Attachments] See images for this press release:
Altering cellular interactions around amyloid plaques may offer novel Alzheimer’s treatment strategies Altering cellular interactions around amyloid plaques may offer novel Alzheimer’s treatment strategies 2

ELSE PRESS RELEASES FROM THIS DATE:

Brain damage reveals part of the brain necessary for helping others

2024-05-27
Our willingness to help others is governed by a specific brain region pinpointed by researchers in a study of patients with brain damage to that region.  Learning about where in the brain ‘helping’ decisions are made is important for understanding how people might be motivated to tackle large global challenges, such as climate change, infectious disease and international conflict. It is also essential for finding new approaches to treating disorders of social interactions.   The study, ...

Surprising properties of elastic turbulence discovered

Surprising properties of elastic turbulence discovered
2024-05-27
Blood, lymph fluid and other biological liquids can have surprising and sometimes troubling properties. Many of these biological solutions are non-Newtonian fluids, a type of liquid that is characterized by a non-linear relationship between stress and strain. Consequently, non-Newtonian fluids don’t necessarily behave as one would expect from a liquid. For example, some of these peculiar fluids deform when touched lightly but will act almost as a solid when a strong force is applied.  And biological ...

Study assesses cancer-related care at US hospitals predominantly serving minority populations compared with non-minority serving hospitals

2024-05-27
It’s important to ensure that care provided at US hospitals that predominantly serve Black and Hispanic populations is as high-quality as the care provided at other US hospitals. New research reveals significant disparities in the delivery of cancer-related care at minority serving hospitals (MSHs) compared with non-MSHs, however. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society. For the study, investigators analyzed information from the National Cancer Database (which accrues approximately 70% of US cancer diagnoses) to identify patients eligible for definitive ...

First in-human investigator-initiated clinical trial to launch for refractory prostate cancer patients: Novel alpha therapy targets prostate-specific membrane antigen

First in-human investigator-initiated clinical trial to launch for refractory prostate cancer patients: Novel alpha therapy targets prostate-specific membrane antigen
2024-05-27
Osaka, Japan - A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models. This will be a world-first in-human clinical trial with [At-211] PSMA-5. Prostate cancer is on the rise worldwide and is the most commonly diagnosed new cancer in men in Japan. Various treatments are offered for prostate cancer, but the prognosis is very poor when the disease is resistant to standard treatment and associated with multiple metastases. In ...

Will generative AI change the way universities communicate?

2024-05-27
Since the launch of ChatGPT 3 in November 2022, we've been abuzz with talk of artificial intelligence: is it an unprecedented opportunity, or will it rob everyone of jobs and creativity? As we debate on social media (and perhaps use ChatGPT almost daily), generative AIs have also entered the arena of university communication. These tools—based on “Large Language Models” that were optimized for interactive communication—can indeed support, expand, and innovate university communication ...

Artificial Intelligence could help cure loneliness, says expert

2024-05-27
Artificial Intelligence (AI) technology could offer companionship to lonely people amid an international epidemic of loneliness, says a robotics expert. Tony Prescott, a professor of cognitive robotics at the University of Sheffield, argues in his new book The Psychology of Artificial Intelligence that ‘relationships with AIs could support people’ with forms of social interaction.. Loneliness has been found to seriously impair human health, and Professor Prescott makes a case that advances in AI technology could ...

Echidnapus identified from an ‘Age of Monotremes’

Echidnapus identified from an ‘Age of Monotremes’
2024-05-26
Published today in the Alcheringa: An Australasian Journal of Palaeontology, evidence of an ‘Age of Monotremes’ has been unearthed by a team of Australian scientists at the Australian Museum (AM), Museums Victoria and Australian Opal Centre. The findings were led by two renowned mammalogists, Honorary Associate of the Australian Museum, Professor Tim Flannery; and Professor Kris Helgen, Chief Scientist and Director of the Australian Museum Research Institute (AMRI). Found in the Lightning Ridge opal fields, NSW, the opalised jaws ...

Semaglutide may protect kidney function in individuals with overweight or obesity and cardiovascular disease

2024-05-25
The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular disease but without diabetes.1 Unveiling the results today at the 61st ERA Congress, researchers presented the impressive secondary analysis from the SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) trial, a randomised trial comprising a participant pool of 17,604 individuals. Experts believe the study’s results offer hope for those affected by obesity, a condition known ...

New technique detects novel biomarkers for kidney diseases with nephrotic syndrome

2024-05-25
A groundbreaking study, presented today at the 61st ERA Congress, has uncovered a significant breakthrough in the diagnosis and monitoring of kidney diseases associated with nephrotic syndrome.1 Using a hybrid technique, researchers identified anti-nephrin autoantibodies as a reliable biomarker for tracking disease progression, opening new avenues for personalised treatment approaches. Nephrotic syndrome, characterised by elevated protein levels in the urine, is linked to kidney diseases such as minimal change disease (MCD), primary focal segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN). The primary cause behind nephrotic syndrome is damage to podocytes, the ...

Political elites take advantage of anti-partisan protests to disrupt politics

Political elites take advantage of anti-partisan protests to disrupt politics
2024-05-24
Protest movements that reject political parties have an unintended consequence, according to new research from the University of Notre Dame: They empower savvy politicians who channel them to shake up the status quo. The findings provide a framework for understanding recent global political realignments and offer lessons for activists who want to make a meaningful impact. They are particularly relevant in an era when mass protests have become an increasingly common tool to voice dissent with powerful institutions and draw attention to overlooked issues ranging from climate and conflict ...

LAST 30 PRESS RELEASES:

Discovery of spontaneous inflow and outflow states of high-temperature plasma by energetic ions

Tax the rich, say a majority of adults across 17 G20 countries surveyed

Semaglutide leads to greater weight loss in women than men with HF, improves HF symptoms in both sexes

12.5, the 1st Impact Factor of COMMTR released!

Circadian clock impact on cluster headaches funded by $2.4M NIH grant for UTHealth Houston research

Study identifies first drug therapy for sleep apnea

How old is your bone marrow?

Boosting biodiversity without hurting local economies

ChatGPT is biased against resumes with credentials that imply a disability — but it can improve

Simple test for flu could improve diagnosis and surveillance

UT Health San Antonio researcher awarded five-year, $2.53 million NIH grant to study alcohol-assisted liver disease

Giving pre-med students hands-on clinical training

CAMH research suggests potential targets for prevention and early identification of psychotic disorders

Mapping the heart to prevent damage caused by a heart attack

Study challenges popular idea that Easter islanders committed ‘ecocide’

Chilling discovery: Study reveals evolution of human cold and menthol sensing protein, offering hope for future non-addictive pain therapies.

Elena Beccalli, new rector of Università Cattolica del Sacro Cuore, takes office on 1st July

Pacific Northwest Research Institute uncovers hidden DNA mechanisms of rare genetic diseases

Empowering older adults: Wearable tech made easier with personalized support

Pennington Biomedical researchers partner on award-winning Long Covid study

Cooling ‘blood oranges’ could make them even healthier – a bonus for consumers

Body image and overall health found important to the sexual health of older gay men, according to new studies

Lab-grown muscles reveal mysteries of rare muscle diseases

Primary hepatic angiosarcoma: Treatment options for a rare tumor

Research finds causal evidence tying cerebral small-vessel disease to Alzheimer’s, dementia

Navigating the Pyrocene: Recent Cell Press papers on managing fire risk

Restoring the Great Salt Lake would have environmental justice as well as ecological benefits

Cannabis, tobacco use, and COVID-19 outcomes

A 5:2 intermittent fasting meal replacement diet and glycemic control for adults with diabetes

Scientists document self-propelling oxygen decline in the oceans

[Press-News.org] Altering cellular interactions around amyloid plaques may offer novel Alzheimer’s treatment strategies
Innovative research from Mount Sinai also identifies new pathways for research